Publication | Closed Access

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Checkmate 238Surgical OncologyMedicineMelanomaPathologyImmune Checkpoint InhibitorImmunotherapeuticsVersus IpilimumabCancer TreatmentStage Iv MelanomaImmunotherapyOncologyRadiation OncologyMolecular Oncology